Biotech Values

[north40000]

We like VKTX also….our holdings were purchased at end of November 2022, so we currently have a LTCG.

AVXL is reported to have filed an application in EU, naming AD and perhaps Retts and Parkinson’s as indication(s) to be treated with Blarcasimine(sp?).

The Phase 3 BRAVE trial of Amarin’s Vascepa, orally dosed in cognitively healthy adults at 4 gms/day, completed 9/29/2023. Dr. Cynthia Carlsson, U. Wisconsin, is P.I. It appears top-line results may be reported this year, and full results by end of March 2024. https://reporter.nih.gov/project-details/9031632 has further description when all links are clicked.